C Pinto

Summary

Affiliation: University of Bologna
Country: Italy

Publications

  1. ncbi Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study
    C Pinto
    Division of Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Am J Clin Oncol 24:143-7. 2001
  2. ncbi Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)
    C Pinto
    Medical Oncology Unit, S Orsola Malpighi Hospital, Via Albertoni 15, Bologna, Italy
    Ann Oncol 22:2424-30. 2011
  3. ncbi A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
    F De Vita
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi e A Lanzara, Second University of Naples, Via Pansini 5, Naples 80131, Italy
    Br J Cancer 104:427-32. 2011
  4. ncbi Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study
    A Martoni
    U O di Oncologia Medica, Dipartimento di Oncologia e Ematologia, Policlinico S Orsola Malpighi, Via Albertoni 15, 40138 Bologna, Italy
    Anticancer Res 23:687-91. 2003
  5. ncbi Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma
    A Martoni
    Department of Oncology and Haematology, S. Orsola-Malpighi Hospital, Bologna, Italy
    Ann Oncol 12:519-24. 2001
  6. ncbi Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
    C Pinto
    Department of Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Br J Cancer 101:1261-8. 2009
  7. ncbi Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
    C Pinto
    Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Ann Oncol 18:510-7. 2007
  8. ncbi MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease
    C Pinto
    Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
    Br J Cancer 95:752-6. 2006

Collaborators

Detail Information

Publications8

  1. ncbi Combination chemotherapy with mitoxantrone, methotrexate, and mitomycin (MMM regimen) in malignant pleural mesothelioma: a phase II study
    C Pinto
    Division of Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Am J Clin Oncol 24:143-7. 2001
    ..8%, 13.6%, and 22.7% of patients, respectively. From the data presented here, this regimen can be considered active in the treatment of malignant pleural mesothelioma...
  2. ncbi Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study)
    C Pinto
    Medical Oncology Unit, S Orsola Malpighi Hospital, Via Albertoni 15, Bologna, Italy
    Ann Oncol 22:2424-30. 2011
    ..The aim of this phase II study was to assess the activity of panitumumab in combination with oxaliplatin, 5-fluorouracil, and external radiotherapy (RT) as preoperative treatment in locally advanced rectal cancer patients...
  3. ncbi A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
    F De Vita
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi e A Lanzara, Second University of Naples, Via Pansini 5, Naples 80131, Italy
    Br J Cancer 104:427-32. 2011
    ..Preoperative chemoradiotherapy (CRT) improves the survival of patients with oesophageal cancer when compared with surgery alone...
  4. ncbi Oxaliplatin plus raltitrexed in the treatment of patients with advanced colorectal cancer: a phase II study
    A Martoni
    U O di Oncologia Medica, Dipartimento di Oncologia e Ematologia, Policlinico S Orsola Malpighi, Via Albertoni 15, 40138 Bologna, Italy
    Anticancer Res 23:687-91. 2003
    ..The reasons for the low activity observed could at least in part be related to a reduction in the RTX dose intensity...
  5. ncbi Oxaliplatin and protracted continuous 5-fluorouracil infusion in patients with pretreated advanced colorectal carcinoma
    A Martoni
    Department of Oncology and Haematology, S. Orsola-Malpighi Hospital, Bologna, Italy
    Ann Oncol 12:519-24. 2001
    ....
  6. ncbi Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)
    C Pinto
    Department of Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Br J Cancer 101:1261-8. 2009
    ..The purpose of this phase II study was to evaluate the activity and safety of cetuximab combined with cisplatin and docetaxel as a first-line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma...
  7. ncbi Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
    C Pinto
    Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
    Ann Oncol 18:510-7. 2007
    ..The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma...
  8. ncbi MSH6 germline mutations in early-onset colorectal cancer patients without family history of the disease
    C Pinto
    Department of Genetics, Portuguese Oncology Institute, Porto, Portugal
    Br J Cancer 95:752-6. 2006
    ..Further studies are warranted to understand the genetic and environmental factors responsible for the variable penetration of MSH6 germline mutations, as well as to identify other causes of early-onset colorectal cancer...